部門紹介

研究業績

最終更新日 : 2017年6月14日

目次

  1. 原著論文
  2. 解説・総説や教科書など

原著論文

2017年

K. Hosoya, S. Matsusaka, T. Kashiwada, K. Suzuki, N. Ureshino, A. Sato, Y. Miki, K. Kitera, M. Hirai, K. Hatake, S. Kimura and N. Sueoka-Aragane.
Detection of KRAS mutations in plasma DNA using a fully automated Rrpid detection system in colorectal cancer patients.
Pathol. Oncol. Res., in press (2017)

このページのTOPへ

2016年

A. Dobashi, N. Tsuyama, R. Asaka, Y. Togashi, K. Ueda, S. Sakata, S. Baba, K. Sakamoto, K. Hatake and K. Takeuchi.
Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.
Genes Chromosomes Cancer, 55, 460-71 (2016)
I. Fukada, K. Araki, K. Kobayashi, T. Shibayama, S. Takahashi, R. Horii, F. Akiyama, T. Iwase, S. Ohno, K. Hatake, Y. Hozumi, N. Sata and Y. Ito.
Predictive factors and value of ypN+ after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer.
PLoS One, 11, e0162616 (2016)
A. Goy, A. Forero, N. Wagner-Johnston, W. Christopher Ehmann, M. Tsai, K. Hatake, R. Ananthakrishnan, A. Volkert, E. Vandendries and M. Ogura.
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Br. J. Haematol., 174, 571-81 (2016)
A. Harada, M. Oguchi, Y. Terui, K. Takeuchi, M. Igarashi, T. Kozuka, K. Harada, T. Uno and K. Hatake.
Radiation therapy for localized duodenal low-grade follicular lymphoma.
J. Radiat. Res., 57, 412-417 (2016)
K. Hatake, T. Doi, H. Uetake, Y. Takahashi, Y. Ishihara and K. Shirao.
Bevacizumab safety in Japanese patients with colorectal cancer.
Jpn. J. Clin. Oncol, 46, 234-40 (2016)
K. Kobayashi, Y. Ito, M. Matsuura, I. Fukada, R. Horii, S. Takahashi, F. Akiyama, T. Iwase, Y. Hozumi, Y. Yasuda and K. Hatake.
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer.
Surg. Today, 47, 821-6 (2016)
Y. Kusano, N. Nishimura, M. Yokoyama, Y. Terui and K. Hatake.
Gastric involvement, a rare site for extramedullary myeloma.
Ann. Hematol., 95, 663-4 (2016)
Y. Kusano, Y. Terui, N. Nishimura, M. Yokoyama, K. Ueda and K. Hatake.
Myelomatous meningitis: a case report.
Int. J. Hematol., 104, 149-50 (2016)
Y. Kusano, Y. Terui, K. Ueda and K. Hatake.
Epstein-Barr virus gastric ulcer associated with ruxolitinib.
Ann. Hematol., 95, 1741-2 (2016)
Y. Kusano, Y. Terui, K. Ueda and K. Hatake.
Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
Ann. Hematol., 95, 1561-2 (2016)
Y. Kusano, Y. Terui, M. Yokoyama and K. Hatake.
Lichenoid drug eruption associated with Bendamustine.
Blood Cancer J., 6, e438 (2016)
D. Maruyama, H. Nagai, N. Fukuhara, T. Kitano, T. Ishikawa, H. Shibayama, I. Choi, K. Hatake, T. Uchida, M. Nishikori, T. Kinoshita, Y. Matsuno, T. Nishikawa, S. Takahara and K. Tobinai.
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Cancer Sci., 107, 1785-90 (2016)
M. Ogura, K. Tobinai, K. Hatake, A. Davies, M. Crump, R. Ananthakrishnan, T. Ishibashi, M. L. Paccagnella, J. Boni, E. Vandendries and D. MacDonald.
Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Clin. Cancer Res., 22, 4807-4816 (2016)
Y. Shigematsu, M. Matsuura, N. Nishimura, N. Tsuyama, K. Takeuchi, Y. Terui, N. Takeshima and K. Hatake.
Intravascular large B-cell lymphoma of bilateral ovaries and the uterus in an asymptomatic patient with a t(11;22)(q23;q11) constitutional translocation.
Intern. Med., 55, 3169-74 (2016)
K. Suzuki, A. Shinagawa, T. Uchida, M. Taniwaki, H. Hirata, K. Ishizawa, K. Matsue, Y. Ogawa, T. Shimizu, M. Otsuka, M. Matsumoto, S. Iida, Y. Terui, I. Matsumura, T. Ikeda, N. Takezako, Y. Ogaki, S. Midorikawa, V. Houck, A. Ervin-Haynes and T. Chou.
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study.
Cancer Sci., 107, 653-8 (2016)

このページのTOPへ

2015年

Nitta, H., Terui, Y., Yokoyama, M., Mishima, Y., Nishimura, N., Ueda, K., Kusano, Y., Tsuyama, N., Takeuchi, K., Kanda, Y., Hatake, K.
Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.
Haematologica, 100, 87-90 (2015)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S., Hatake, K.
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Breast Cancer, 22, 177-184 (2015)
Roccaro, A.M., Mishima, Y., Sacco, A., Moschetta, M., Tai, Y.T., Shi, J., Zhang, Y., Reagan, M.R., Huynh, D., Kawano, Y., Sahin, I., Chiarini, M., Manier, S., Cea, M., Aljawai, Y., Glavey, S., Morgan, E., Pan, C., Michor, F., Cardarelli, P., Kuhne, M., Ghobrial, I.M.
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation.
Cell Rep, 12, 622-635 (2015)
Suzuki, S., Matsusaka, S., Hirai, M., Shibata, H., Takagi, K., Mizunuma, N., Hatake, K.
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.
Int J Oncol, 47, 97-105 (2015)

このページのTOPへ

2014年

Kodama, T., Motoi, N., Ninomiya, H., Sakamoto, H., Kitada, K., Tsukaguchi, T., Satoh, Y., Nomura, K., Nagano, H., Ishii, N., Terui, Y., Hatake, K., Ishikawa, Y.
A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell Ll.
J Thorac Oncol, 9, 1638-1646 (2014)
Matsusaka, S., Kozuka, M., Takagi, H., Ito, H., Minowa, S., Hirai, M., Hatake, K.
A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid.
Cancer Lett, 355, 113-120 (2014)

このページのTOPへ

2013年

Doi, T., Hamaguchi, T., Shirao, K., Chin, K., Hatake, K., Noguchi, K., Otsuki, T., Mehta, A., Ohtsu, A.
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Int J Clin Oncol, 18, 87-95 (2013)
Kuboki, Y., Matsusaka, S., Minowa, S., Shibata, H., Suenaga, M., Shinozaki, E., Mizunuma, N., Ueno, M., Yamaguchi, T., Hatake, K.
Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer.
Anticancer Res, 33, 3905-3910 (2013)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S.
Diverticular bleeding of the colon during combination chemotherapy with bevacizumab and paclitaxel for recurrent breast cancer.
Case Rep Oncol, 6, 50-54 (2013)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S., Hatake, K.
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Breast Cancer, in press (2013)
Ogura, M., Hatake, K., Tobinai, K., Uchida, T., Suzuki, T., Terui, Y., Yokoyama, M., Maruyama, D., Mori, M., Jewell, R.C., Katsura, K., Hotta, T.
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jpn J Clin Oncol, 43, 466-475 (2013)
Ogura, M., Tobinai, K., Hatake, K., Uchida, T., Suzuki, T., Kobayashi, Y., Mori, M., Terui, Y., Yokoyama, M., Hotta, T.
Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Cancer Sci, 104, 105-110 (2013)
Suzuki, K., Terui, Y., Nishimura, N., Mishima, Y., Sakajiri, S., Yokoyama, M., Takahashi, S., Tsuyama, N., Takeuchi, K., Hatake, K.
Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.
Jpn J Clin Oncol, 43, 37-44 (2013)
Suzuki, K., Terui, Y., Yokoyama, M., Ueda, K., Nishimura, N., Mishima, Y., Sakajiri, S., Tsuyama, N., Takeuchi, K., Hatake, K.
Prognostic value of high thymidine kinase activity in previously untreated diffuse large B-cell lymphoma patients treated by R-CHOP.
Leuk Lymphoma, 54, 2412-2417 (2013)
Takagi, S., Sato, S., Oh-Hara, T., Takagi, M., Koike, S., Mishima, Y., Hatake, K., Fujita, N.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/Podoplanin and CLEC-2.
PLoS One, 8, e73609 (2013)
Ueda, K., Terui, Y., Yokoyama, M., Sakajiri, S., Nishimura, N., Tsuyama, N., Takeuchi, K., Hatake, K.
Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Leuk Lymphoma, 54, 1928-1933 (2013)
Yokoyama, M., Terui, Y., Takeuchi, K., Nara, E., Nakano, K., Ueda, K., Nishimura, N., Mishima, Y., Sakajiri, S., Tsuyama, N., Ozawa, K., Hatake, K.
Infusion rate escalation study of rituximab in patients with CD20+ B-cell lymphomas: A single institution analysis in Japan.
ISRN Oncol, 2013:863909 (2013)

このページのTOPへ

2012年

Hosonaga, M., Ito, Y., Tokudome, N., Takahashi, S., Iwase, T., Hatake, K.
A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Breast Cancer, 19, 329-334 (2012)
Ito, Y.
Should we treat minimal breast cancer lesions?
Breast Cancer, 19, 93-94 (2012)
Ito, Y., Iwase, T., Hatake, K.
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Breast Cancer, 19, 206-2011 (2012)
Ito, Y., Suenaga, M., Hatake, K., Takahashi, S., Yokoyama, M., Onozawa, Y., Yamazaki, K., Hironaka, S., Hashigami, K., Hasegawa, H., Takenaka, N., Boku, N.
Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: A phase 1 dose-escalation study.
Jpn J Clin Oncol, 42, 278-286 (2012)
Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S., Maekawa, T., Habuchi, T.
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Int J Cancer, 130, 677-684 (2012)
Mishima, Y., Terui, Y., Kuniyoshi, R., Matsusaka, S., Mikuniya, M., Kojima, K., Hatake, K.
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism.
Int Immunol, 24, 477-483 (2012)
Takahashi, S., Iwase, T., Kohno, N., Ishikawa, T., Taguchi, T., Takahashi, M., Horiguchi, J., Nakamura, S., Hozumi, Y., Fukunaga, M., Noguchi, S.
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Breast Cancer Res Treat, 133, 685-693 (2012)
Yuasa, T., Tsuchiya, N., Urakami, S., Horikawa, Y., Narita, S., Inoue, T., Saito, M., Yamamoto, S., Yonese, J., Fukui, I., Nakano, K., Takahashi, S., Hatake, K., Habuchi, T.
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int, 109, 1394-1354 (2012)

このページのTOPへ

2011年

Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., Yamamoto, N.
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
Invest New Drugs, in press (2011)
Hosonaga, M., Ito, Y., Tokudome, N., Takahashi, S., Iwase, T., Hatake, K.
A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Breast Cancer, in press (2011)
Ito, Y., Iwase, T., Hatake, K.
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Breast Cancer, in press (2011)
Ito, Y., Nagasaki, K., Miki, Y., Iwase, T., Akiyama, F., Matsuura, M., Horii, R., Makita, M., Tokudome, N., Ushijima, M., Yoshimoto, M., Takahashi, S., Noda, T., Hatake, K.
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Cancer Sci, 102, 130-136 (2011)
Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S., Maekawa, T., Habuchi, T.
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Int J Cancer, (2011)
Matsusaka, S., Mishima, Y., Suenaga, M., Terui, Y., Kuniyoshi, R., Mizunuma, N., Hatake, K.
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Cancer, 117, 4026-4032 (2011)
Okanami, Y., Ito, Y., Watanabe, C., Iijima, K., Iwase, T., Tokudome, N., Takahashi, S., Hatake, K.
Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
Breast Cancer, (2011)
Oyama, M., Nagashima, T., Suzuki, T., Kozuka-Hata, H., Yumoto, N., Shiraishi, Y., Ikeda, K., Kuroki, Y., Gotoh, N., Ishida, T., Inoue, S., Kitano, H., Okada-Hatakeyama, M.
Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.
J Biol Chem, 286, 818-829 (2011)
Suenaga, M., Matsusaka, S., Ueno, M., Yamamoto, N., Shinozaki, E., Mizunuma, N., Yamaguchi, T., Hatake, K.
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Surg Today, 41, 1067-1074 (2011)
Suenaga, M., Matsusaka, S., Watanabe, T., Kuboki, Y., Shinozaki, E., Chin, K., Mizunuma, N., Ueno, M., Yamaguchi, T., Hatake, K.
How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
Asia Pac J Clin Oncol, 7, 129-135 (2011)
Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., Hatake, K.
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Cancer Sci, 102, 2058-2064 (2011)
Tokudome, N., Ito, Y., Takahashi, S., Kobayashi, K., Taira, S., Tsutsumi, C., Oto, M., Oba, M., Inoue, K., Kuwayama, A., Masumura, K., Nakayama, Y., Watanabe, C., Hatake, K.
Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
Breast Cancer, 18, 195-202 (2011)
Yuasa, T., Takahashi, S., Hatake, K., Yonese, J., Fukui, I.
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Cancer Sci, in press (2011)
Yuasa, T., Tsuchiya, N., Urakami, S., Horikawa, Y., Narita, S., Inoue, T., Saito, M., Yamamoto, S., Yonese, J., Fukui, I., Nakano, K., Takahashi, S., Hatake, K., Habuchi, T.
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int, (2011)
Yuasa, T., Urakami, S., Yamamoto, S., Yonese, J., Nakano, K., Kodaira, M., Takahashi, S., Hatake, K., Inamura, K., Ishikwa, Y., Fukui, I.
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Urology, 77, 831-835 (2011)
Yuasa, T., Urakami, S., Yamamoto, S., Yonese, J., Saito, K., Takahashi, S., Hatake, K., Fukui, I.
Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
Clin Exp Metastasis, 28, 405-411 (2011)

このページのTOPへ

2010年

Asai, H., Yokoyama, M., Terui, Y., Ennishi, D., Takeuchi, K., Hatake, K.
Is statin use really associated with efficacy of rituximab?
J Clin Oncol, 28, e424-425; author reply e427-428 (2010)
Ennishi, D., Asai, H., Maeda, Y., Shinagawa, K., Ikeda, K., Yokoyama, M., Terui, Y., Takeuchi, K., Yoshino, T., Matsuo, K., Hatake, K., Tanimoto, M.
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ann Oncol, 21, 1217-1221 (2010)
Hijioka, S., Chin, K., Seto, Y., Yamamoto, N., Hatake, K.
Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.
World J Gastroenterol, 16, 2824-2827 (2010)
Ito, Y., Nagasaki, K., Miki, Y., Iwase, T., Akiyama, F., Matsuura, M., Horii, R., Makita, M., Tokudome, N., Ushijima, M., Yoshimoto, M., Takahashi, S., Noda, T., Hatake, K.
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Cancer Sci, 102, 130-136 (2010)
Kodaira, M., Takahashi, S., Takeuchi, K., Yuasa, T., Saotome, T., Yonese, J., Fukui, I., Hatake, K.
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Ann Oncol, 21, 1563-1565 (2010)
Kodaira, M., Takahashi, S., Yamada, S., Ueda, K., Mishima, Y., Takeuchi, K., Yamamoto, N., Ishikawa, Y., Yokoyama, M., Saotome, T., Terui, Y., Hatake, K.
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Ann Oncol, 21, 1163-1167 (2010)
Matsusaka, S., Chin, K., Ogura, M., Suenaga, M., Shinozaki, E., Mishima, Y., Terui, Y., Mizunuma, N., Hatake, K.
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Cancer Sci, 101, 1067-1071 (2010)
Suenaga, M., Mizunuma, N., Kobayashi, K., Shinozaki, E., Matsusaka, S., Chin, K., Kuboki, Y., Ichimura, T., Ozaka, M., Ogura, M., Fujiwara, Y., Matsueda, K., Konishi, F., Hatake, K.
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Med Oncol, 27, 807-814 (2010)
Suenaga, M., Mizunuma, N., Kobayashi, K., Shinozaki, E., Matsusaka, S., Chin, K., Kuboki, Y., Ichimura, T., Ozaka, M., Ogura, M., Fujiwara, Y., Matsueda, K., Konishi, F., Hatake, K.
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Med Oncol, 27, 807-814 (2010)
Uemura, H., Shinohara, N., Yuasa, T., Tomita, Y., Fujimoto, H., Niwakawa, M., Mugiya, S., Miki, T., Nonomura, N., Takahashi, M., Hasegawa, Y., Agata, N., Houk, B., Naito, S., Akaza, H.
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Jpn J Clin Oncol, 40, 194-202 (2010)
Yuasa, T., Maita, S., Tsuchiya, N., Ma, Z., Narita, S., Horikawa, Y., Yamamoto, S., Yonese, J., Fukui, I., Takahashi, S., Hatake, K., Habuchi, T.
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Urology, 75, 1131-1137 (2010)

このページのTOPへ

2009年

Ennishi, D., Yokoyama, M., Terui, Y., Asai, H., Sakajiri, S., Mishima, Y., Takahashi, S., Komatsu, H., Ikeda, K., Takeuchi, K., Tanimoto, M., Hatake, K.
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ann Oncol, 20, 526-533 (2009)
Ito, Y., Osaki, Y., Tokudome, N., Sugihara, T., Takahashi, S., Iwase, T., Hatake, K.
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Breast Cancer, 16, 126-131 (2009)
Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K., Hatake, K.
An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Clin Cancer Res, 15, 3624-3632 (2009)
Mori, M., Nakamoto, S., Akifuji, Y., Tanaka, T., Komatsu, N., Hatake, K., Ozawa, K.
Familial sideroblastic anemia associated with cardiac atrial septal defect.
Am J Hematol, 84, 451-452 (2009)
Morota, M., Gomi, K., Kozuka, T., Chin, K., Matsuura, M., Oguchi, M., Ito, H., Yamashita, T.
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Int J Radiat Oncol Biol Phys, 75, 122-128 (2009)
Osako, T., Ito, Y., Ushijima, M., Takahashi, S., Tokudome, N., Sugihara, T., Iwase, T., Matsuura, M., Hatake, K.
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Cancer Chemother Pharmacol, 63, 865-871 (2009)
Suenaga, M., Mizunuma, N., Chin, K., Matsusaka, S., Shinozaki, E., Oya, M., Ueno, M., Yamaguchi, T., Muto, T., Konishi, F., Hatake, K.
Chemotherapy for Small-Bowel Adenocarcinoma at a Single Institution.
Surgery Today, 39, 27-31 (2009)
Tanabe, M., Ito, Y., Tokudome, N., Sugihara, T., Miura, H., Takahashi, S., Seto, Y., Iwase, T., Hatake, K.
Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Breast Cancer, 16, 301-306 (2009)
Terui, Y., Mishima, Y., Sugimura, N., Kojima, K., Sakurai, T., Kuniyoshi, R., Taniyama, A., Yokoyama, M., Sakajiri, S., Takeuchi, K., Watanabe, C., Takahashi, S., Ito, Y., Hatake, K.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Clin Cancer Res, 15, 2523-2530 (2009)
Wang, W., Yuasa, T., Tsuchiya, N., Ma, Z., Maita, S., Narita, S., Kumazawa, T., Inoue, T., Tsuruta, H., Horikawa, Y., Saito, M., Hu, W., Ogawa, O., Habuchi, T.
The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Int J Cancer, 125, 2836-2843 (2009)
Yuasa, T.
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Int J Urol, 16, 731-732 (2009)
Yuasa, T., Sato, K., Ashihara, E., Takeuchi, M., Maita, S., Tsuchiya, N., Habuchi, T., Maekawa, T., Kimura, S.
Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model.
Cancer Immunol Immunother, 58, 493-502 (2009)

このページのTOPへ

2008年

Chin, K., Baba, S., Hosaka, H., Ishiyama, A., Mizunuma, N., Shinozaki, E., Suenaga, M., Kozuka, T., Seto, Y., Yamamoto, N., Hatake, K.
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.
Jpn J Clin Oncol, 38, 426-431 (2008)
Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ann Oncol, 19, 1921-1926 (2008)
Ennishi, D., Terui, Y., Yokoyama, M., Mishima, Y., Takahashi, S., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Increased incidence of interstitial pneumonia by CHOP combined with rituximab.
Int J Hematol, 87, 393-397 (2008)
Ennishi, D., Terui, Y., Yokoyama, M., Mishima, Y., Takahashi, S., Takeuchi, K., Okamoto, H., Tanimoto, M., Hatake, K.
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
Am J Hematol, 83, 59-62 (2008)
Ennishi, D., Yokoyama, M., Terui, Y., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Does rituximab really induce hepatitis C virus reactivation?
J Clin Oncol, 26, 4695-4696; author reply 4696 (2008)
Osako, T., Ito, Y., Takahashi, S., Tokudome, N., Iwase, T., Hatake, K.
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Cancer Chemother Pharmacol, 62, 159-164 (2008)
Saito, F., Matsusaka, S., Takahashi, Y., Wakabayashi, I.
Enhancement of nitric oxide synthase induction in alveolar macrophages by in vivo administration of docetaxel.
Eur J Pharmacol, 580, 425-430 (2008)
Suenaga, M., Mizunuma, N., Shinozaki, E., Matsusaka, S., Chin, K., Muto, T., Konishi, F., Hatake, K.
Management of allergic reactions to oxaliplatin in colorectal cancer patients.
J Support Oncol, 6, 373-378 (2008)
Suenaga, M., Mizunuma, N., Shouji, D., Shinozaki, E., Matsusaka, S., Chin, K., Oya, M., Yamaguchi, T., Muto, T., Hatake, K.
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
J Gastroenterol, 43, 842-848 (2008)
Tokudome, N., Ito, Y., Hatake, K., Toi, M., Sano, M., Iwata, H., Sato, Y., Saeki, T., Aogi, K., Takashima, S.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
Anticancer Drugs, 19, 753-759 (2008)

このページのTOPへ

2007年

Boku, N., Ohtsu, A., Hyodo, I., Shirao, K., Miyata, Y., Nakagawa, K., Tamura, T., Hatake, K., Tanigawara, Y.
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
Jpn J Clin Oncol, 37, 440-445 (2007)
Ennishi, D., Yokoyama, M., Mishima, Y., Watanabe, C., Terui, Y., Takahashi, S., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Leuk Lymphoma, 48, 2241-2243 (2007)
Hatake, K., Tokudome, N., Ito, Y.
5. Tanstuzumab treatment for breast cancer.
Intern Med, 46, 149-150 (2007)
Hatake, K., Tokudome, N., Ito, Y.
Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
Breast Cancer, 14, 132-149 (2007)
Ito, Y., Tokudome, N., Sugihara, T., Takahashi, S., Hatake, K.
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Breast Cancer, 14, 156-162 (2007)
Matsusaka, S., Yamasaki, H., Fukushima, M., Wakabayashi, I.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Chemotherapy, 53, 36-41 (2007)
Mishima, Y., Terui, Y., Sugimura, N., Matsumoto-Mishima, Y., Rokudai, A., Kuniyoshi, R., Hatake, K.
Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells.
Cancer Sci, 98, 364-372 (2007)
Mitsuhashi, J., Tsukahara, S., Suzuki, R., Oh-hara, Y., Nishi, S., Hosoyama, H., Katayama, K., Noguchi, K., Minowa, S., Shibata, H., Ito, Y., Hatake, K., Aiba, K., Takahashi, S., Sugimoto, Y.
Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer.
Hum Gene Ther, 18, 895-906 (2007)
Morimoto, H., Takahashi, M., Shiba, Y., Izawa, A., Ise, H., Hongo, M., Hatake, K., Motoyoshi, K., Ikeda, U.
Bone marrow-derived CXCR4+ cells mobilized by macrophage colony-stimulating factor participate in the reduction of infarct area and improvement of cardiac remodeling after myocardial infarction in mice.
Am J Pathol, 171, 755-766 (2007)
Osako, T., Ito, Y., Morimatsu, A., Tada, K., Sakurai, N., Takahashi, S., Akiyama, F., Iwase, T., Hatake, K.
Flare-up of dermatomyositis along with recurrence of breast cancer.
Breast J, 13, 200-202 (2007)
Osako, T., Ito, Y., Takahashi, S., Tokudome, N., Iwase, T., Hatake, K.
Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer.
Tumori, 93, 129-132 (2007)
Shiba, Y., Takahashi, M., Yoshioka, T., Yajima, N., Morimoto, H., Izawa, A., Ise, H., Hatake, K., Motoyoshi, K., Ikeda, U.
M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system.
Arterioscler Thromb Vasc Biol, 27, 283-289 (2007)
Takahashi, S., Aiba, K., Ito, Y., Hatake, K., Nakane, M., Kobayashi, T., Minowa, S., Shibata, H., Mitsuhashi, J., Tsukahara, S., Ishikawa, E., Suzuki, R., Tsuruo, T., Sugimoto, Y.
Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
Cancer Sci, 98, 1609-1616 (2007)
Utsubo-Kuniyoshi, R., Terui, Y., Mishima, Y., Rokudai, A., Sugimura, N., Kojima, K., Sonoda, Y., Kasahara, T., Hatake, K.
MEK-ERK is involved in SUMO-1 foci formation on apoptosis.
Cancer Sci, 98, 569-576 (2007)
Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., Terui, Y., Ruthardt, M., Ueda, T., Hatake, K., Inui, K., Maekawa, T.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Blood, 109, 306-314 (2007)

このページのTOPへ

2006年

Ennishi, D., Sezaki, N., Senoo, T., Terui, Y., Hatake, K., Hino, N.
A case of acute promyelocytic leukemia during gefitinib treatment.
Int J Hematol, 84, 284-285 (2006)
Furukawa, K., Ito, Y., Takahashi, S., Sawaki, M., Mizunuma, N., Horikoshi, N., Kasumi, F., Akiyama, F., Sakamoto, G., Furukawa, K., Tajiri, T., Hatake, K.
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Breast Cancer, 13, 329-333 (2006)
Hyodo, I., Shirao, K., Doi, T., Hatake, K., Arai, Y., Yamaguchi, K., Tamura, T., Takemiya, S., Takiuchi, H., Nakagawa, K., Mishima, H.
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Jpn J Clin Oncol, 36, 410-417 (2006)
Kurihara, R., Tohyama, Y., Matsusaka, S., Naruse, H., Kinoshita, E., Tsujioka, T., Katsumata, Y., Yamamura, H.
Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils.
J Biol Chem, 281, 12908-12918 (2006)
Matsusaka, S., Wakabayashi, I.
Enhancement of vascular smooth muscle cell migration by urotensin II.
Naunyn Schmiedebergs Arch Pharmacol, 373, 381-386 (2006)
Mishima, Y., Terui, Y., Takeuchi, K., Nagasaki, E., Yokoyama, M., Mizunuma, N., Takahashi, S., Yamada, K., Fukunaga, T., Yamamoto, J., Yamaguchi, T., Kato, Y., Hatake, K.
Simultaneously occurring chronic myelogenous leukemia andgastrointestinal stromal tumors treated with imatinib.
Targeted Oncology, 1, 168-171 (2006)
Rokudai, A., Terui, Y., Kuniyoshi, R., Mishima, Y., Aizu-Yokota, E., Sonoda, Y., Kasahara, T., Hatake, K.
Differential Regulation of Eotaxin-1/CCL11 and Eotaxin-3/CCL26 Production by the TNF-α and IL-4 Stimulated Human Lung Fibroblast.
Biol Pharm Bull, 29, 1102-1109 (2006)
Sano, M., Tokuda, Y., Noguchi, S., Aogi, K., Saeki, T., Tabei, T., Hatake, K., Fujii, H.
A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer.
Gan To Kagaku Ryoho, 33, 1091-1097 (2006)
Sawaki, M., Ito, Y., Akiyama, F., Tokudome, N., Horii, R., Mizunuma, N., Takahashi, S., Horikoshi, N., Imai, T., Nakao, A., Kasumi, F., Sakamoto, G., Hatake, K.
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Breast Cancer, 13, 172-178 (2006)
Suenaga, M., Oya, M., Ueno, M., Yamamoto, J., Yamaguchi, T., Mizunuma, N., Hatake, K., Kato, Y., Muto, T.
Anal canal carcinoma with Pagetoid spread: report of a case.
Surg Today, 36, 666-669 (2006)
Tada, K., Ito, Y., Takahashi, S., Iijima, K., Miyagi, Y., Nishimura, S., Takahashi, K., Makita, M., Iwase, T., Yoshimoto, M., Kasumi, F.
Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.
Breast Cancer, 13, 279-283 (2006)
Takahashi, S., Ito, Y., Hatake, K., Sugimoto, Y.
Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital.
Breast Cancer, 13, 8-15 (2006)
Takeuchi, K., Tanaka-Taya, K., Kazuyama, Y., Ito, Y.M., Hashimoto, S., Fukayama, M., Mori, S.
Prevalence of Epstein-Barr virus in Japan: trends and future prediction.
Pathol Int, 56, 112-116 (2006)
Terui, Y., Sakurai, T., Mishima, Y., Sugimura, N., Sasaoka, C., Kojima, K., Yokoyama, M., Mizunuma, N., Takahashi, S., Ito, Y., Hatake, K.
Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
Cancer Sci, 97, 72-79 (2006)

このページのTOPへ